The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.
Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.
In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.
Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.
Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.
Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.
An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.
In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.
While breast cancer survivors had a 45% higher risk of going into preterm labor, there were no significant increased risks of congenital defects or other pregnancy or delivery complications.
Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.
Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.
Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.
Recently presented data demonstrated that a combination of oral paclitaxel and Encequidar elicited promising results in patients with radiation-associated breast angiosarcoma.
In addition to having greater efficacy, the combination of oral paclitaxel and encequidar demonstrated lower rates of chemotherapy-induced peripheral neuropathy in patients with metastatic breast cancer compared to intravenous paclitaxel.
Younger age, breast cancer diagnosis, Medicaid insurance and treatment type were associated with an increased risk for women becoming new chronic users of opioids or sedatives/hypnotics following mastectomy with reconstructive surgery.
Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.
At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.
Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.
Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.
Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.
Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.
This massive event for women with breast cancer just may be “man’s breast friend”.
Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.
Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.
Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.
Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.
The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.
